Previous results from our group demonstrated that G28 compound had a synergistic interaction with pertuzumab and temsirolimus in HER2+ breast cancer cells [38] and EGCG with cetuximab in TNBC [51]. This evidence concerns the gene ERBB2 and breast carcinoma.